Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. Issue 2 (17th February 2019)

• Record Type: Journal Article
• Authors: Wada, Ryuta; Matsui, Makoto; Kawasaki, Nana
• Is Part Of: MAbs. Volume 11:Issue 2(2019)
• Page Start: 350
• Page End: 372
• Publication Date: 2019-02-17
• Subjects: Monoclonal antibody (mAb) -- IgG1 -- Fc glycosylation -- chemoenzymatic transglycosylation -- Fc effector functions -- Fc receptor -- antibody-dependent cell-mediated cytotoxicity (ADCC) -- complement dependent cytotoxicity (CDC) -- thermal stability -- protein aggregation; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2018.1551044
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Glycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2 domain is known as N-glycosylation. It is one of the most common post-translational modifications and important critical quality attributes of monoclonal antibody (mAb) therapeutics. Various studies have demonstrated the effects of the Fc N-glycosylation on safety, Fc effector functions, and pharmacokinetics, both dependent and independent of neonatal Fc receptor (FcRn) pathway. However, separation of various glycoforms to investigate the biological and functional relevance of glycosylation is a major challenge, and existing studies often discuss the overall impact of N-glycans, without considering the individual contributions of each glycoform when evaluating mAbs with highly heterogeneous distributions. In this study, chemoenzymatic glycoengineering incorporating an endo-β-N-acetylglucosaminidase (ENGase) EndoS2 and its mutant with transglycosylation activity was used to generate mAb glycoforms with highly homogeneous and well-defined N-glycans to better understand and precisely evaluate the effect of each N-glycan structure on Fc effector functions and protein stability. We demonstrated that the core fucosylation, non-reducing terminal galactosylation, sialylation, and mannosylation of IgG1 mAb N-glycans impact not only on FcγRIIIa binding, antibody-dependent cell-mediated cytotoxicity, and C1q binding, but also FcRn binding, thermal stability and propensity for protein aggregation.